Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594705 | 1.00 | FFAR1 (0.34) | FFAR1AKR1C3AKR1C2APPEEF2K | |
| SCHEMBL1743844 | 1.00 | FFAR1 (0.34) | FFAR1AKR1C3AKR1C2APPEEF2K | |
| SCHEMBL1594707 | 1.00 | FFAR1 (0.34) | FFAR1AKR1C3AKR1C2APPEEF2K | |
| SCHEMBL1595344 | 0.83 | FFAR1 (0.32) | FFAR1EEF2KSLC6A9UTS2RPPARG | |
| SCHEMBL1595345 | 0.83 | FFAR1 (0.32) | FFAR1EEF2KSLC6A9UTS2RPPARG | |
| SCHEMBL2547936 | 0.83 | FFAR1 (0.32) | FFAR1EEF2KSLC6A9UTS2RPPARG | |
| SCHEMBL2547934 | 0.83 | FFAR1 (0.32) | FFAR1EEF2KSLC6A9UTS2RPPARG | |
| SCHEMBL1595011 | 0.81 | AKR1C3 (0.40) | FFAR1AKR1C3AKR1C2APPEEF2K | |
| SCHEMBL1595880 | 0.78 | AKR1C3 (0.39) | FFAR1AKR1C3AKR1C2EEF2KCES2 | |
| SCHEMBL1742950 | 0.77 | CES2 (0.37) | FFAR1AKR1C3AKR1C2EEF2KCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | FFAR1 381/4885AKR1C3 1560/4885AKR1C2 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.